Revenue Comparison
Chart: Revenue Comparison. Values in USD billions. In Q2 2026: AstraZeneca 15.384, Viking Therapeutics 0.
AstraZeneca vs Viking Therapeutics Net Worth and Market Cap
AstraZeneca (AZN) and Viking Therapeutics (VKTX) are peers in GLP-1. AstraZeneca reported revenue of $15.4B as of Q2 2026, compared with $0 for Viking Therapeutics. AstraZeneca leads on revenue.
Key differences
- AstraZeneca's KPIs on Sterling include Alliance Revenue by Partnered Medicine (Quarterly) and AZD5004 + AZD6234 Trial Timeline: Oral GLP-1 + Oral Amylin.
- Viking Therapeutics's KPIs on Sterling include Cash + Short-Term Investments (Quarterly) and Viking Oral VK2735 Phase 3 Timing.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, AstraZeneca, Viking Therapeutics.| Metric | AstraZeneca | Viking Therapeutics |
|---|---|---|
| Market Cap | - | - |
| Revenue | $15.38B | $0 |
| Cost of Revenue | $2.52B | $0 |
| Gross Profit | $12.86B | $0 |
| Operating Income | $3.16B | $-164.00M |
| Net Income | $2.51B | $-158.00M |
| R&D Expense | $4.05B | $150.00M |
| Earnings Per Share | $1.59 | -$1.37 |
| Gross Margin | 83.6% | - |
| Operating Margin | 20.6% | - |
| Net Profit Margin | 16.3% | - |
| Free Cash Flow | $2.13B | $-114.00M |
| Cumulative Free Cash Flow | $121.22B | $-747.00M |
| Operating Cash Flow | $2.89B | $-114.00M |
| Cash & Equivalents | $4.89B | $118.00M |